An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer.

CONCLUSION: GMV showed high results in carefully selected patients with low ISF (TGF-β1, IL-10, and VEGF) production. The method should be further investigated in patients with FP. This article is protected by copyright. All rights reserved.
PMID: 32240562 [PubMed - as supplied by publisher]

Source: The Oncologist - April 1, 2020 Category: Cancer & Oncology Authors: Novik A, Danilova AB, Sluzhev MI, Nehaeva TL, Larin SS, Girdyuk DV, Protsenko SA, Semenova AI, Danilov AO, Moiseyenko VM, Georgiev GP, Baldueva IA Tags: Oncologist Source Type: research